[HTML][HTML] SGLT-2 inhibitors in NAFLD: expanding their role beyond diabetes and cardioprotection
Non-alcoholic fatty liver disease (NAFLD) is an 'umbrella'term, comprising a spectrum
ranging from benign, liver steatosis to non-alcoholic steatohepatitis, liver fibrosis and …
ranging from benign, liver steatosis to non-alcoholic steatohepatitis, liver fibrosis and …
[HTML][HTML] Metabolic-Dysfunction-Associated Steatotic Liver Disease—Its Pathophysiology, Association with Atherosclerosis and Cardiovascular Disease, and …
H Yanai, H Adachi, M Hakoshima, S Iida… - International journal of …, 2023 - mdpi.com
Metabolic-dysfunction-associated steatotic liver disease (MASLD) is a chronic liver disease
that affects more than a quarter of the global population and whose prevalence is increasing …
that affects more than a quarter of the global population and whose prevalence is increasing …
SGLT2 inhibition for cardiovascular diseases, chronic kidney disease, and NAFLD
M Ala - Endocrinology, 2021 - academic.oup.com
Abstract Sodium glucose cotransporter 2 (SGLT-2) inhibitors are the latest class of
antidiabetic medications. They prevent glucose reabsorption in the proximal convoluted …
antidiabetic medications. They prevent glucose reabsorption in the proximal convoluted …
Effects of sodium-glucose co-transporter 2 inhibitors on liver fibrosis in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: An updated meta …
Z Jin, Y Yuan, C Zheng, S Liu, H Weng - Journal of Diabetes and its …, 2023 - Elsevier
Background and aim Sodium-glucose co-transporter 2 inhibitors (SGLT2i) has been verified
to improve Non-alcoholic fatty liver disease (NAFLD) in previous clinical practice. We mainly …
to improve Non-alcoholic fatty liver disease (NAFLD) in previous clinical practice. We mainly …
Metabolic dysfunction associated steatotic liver disease and the heart
S Driessen, SM Francque, SD Anker, MC Cabezas… - Hepatology, 2023 - journals.lww.com
The prevalence and severity of metabolic dysfunction associated steatotic liver disease
(MASLD) are increasing. Physicians who treat patients with MASLD may acknowledge the …
(MASLD) are increasing. Physicians who treat patients with MASLD may acknowledge the …
Efficacy and safety of oral semaglutide in patients with non‐alcoholic fatty liver disease complicated by type 2 diabetes mellitus: A pilot study
T Arai, M Atsukawa, A Tsubota, H Ono, T Kawano… - JGH …, 2022 - Wiley Online Library
Abstract Background and Aim This study aimed to clarify the efficacy and safety of oral
semaglutide treatment in patients with non‐alcoholic fatty liver disease (NAFLD) …
semaglutide treatment in patients with non‐alcoholic fatty liver disease (NAFLD) …
[HTML][HTML] The role of anti-diabetic drugs in NAFLD. Have we found the Holy Grail? A narrative review
M Zachou, P Flevari, N Nasiri-Ansari… - European Journal of …, 2024 - Springer
Purpose Non-alcoholic fatty liver disease (NAFLD) has become a leading cause of liver
disease, affecting 30% of the global population. NAFLD prevalence is particularly high in …
disease, affecting 30% of the global population. NAFLD prevalence is particularly high in …
[HTML][HTML] MASLD treatment—a shift in the paradigm is imminent
MV Machado - Frontiers in Medicine, 2023 - frontiersin.org
MASLD prevalence is growing towards the leading cause of end-stage liver disease. Up to
today, the most effective treatment is weight loss. Weight loss interventions are moving from …
today, the most effective treatment is weight loss. Weight loss interventions are moving from …
Effects of dapagliflozin in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials
L Sun, C Deng, Y Gu, Y He, L Yang, J Shi - Clinics and Research in …, 2022 - Elsevier
Background Dapagliflozin as a treatment option in patients with nonalcoholic fatty liver
disease (NAFLD) has received increasing attention, however, the efficacy and safety of …
disease (NAFLD) has received increasing attention, however, the efficacy and safety of …
[HTML][HTML] The potential of SGLT-2 inhibitors in the treatment of polycystic ovary syndrome: the current status and future perspectives
D Rakic, V Jakovljevic, N Jovic, M Bicanin Ilic… - Biomedicines, 2023 - mdpi.com
Polycystic ovary syndrome (PCOS) is the most frequent endocrinopathy during women's
reproductive age. PCOS is a heterogeneous disorder featuring specific cardiometabolic …
reproductive age. PCOS is a heterogeneous disorder featuring specific cardiometabolic …